<DOC>
	<DOCNO>NCT02456571</DOCNO>
	<brief_summary>This pilot study explore prevalence expression four immune checkpoint biomarkers circulate tumor cell ( CTCs ) men metastatic prostate cancer capture EpCAM via CellSearch method , specifically define co express DAPI cytokeratin , lack CD45 expression .</brief_summary>
	<brief_title>CTC Immune Checkpoint</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Patients eligible inclusion study follow criterion apply : 1 . Histologically confirm diagnosis adenocarcinoma prostate . Small cell neuroendocrine tumor prostate also permit . 2 . Clinical radiographic evidence progressive metastatic disease , progression define rise PSA , new metastatic lesion ( bone soft tissue ) , radiographic evidence tumor growth CT MRI . 3 . Age &gt; 18 year . 4 . Ability understand willingness sign write informed consent document . In addition meeting criterion , patient must meet criterion one follow group : A ) mCRPC start abiraterone acetate enzalutamide concurrent sipuleucelT ( Provenge ) 1 . For patient adenocarcinoma prostate ( applicable patient small cell neuroendocrine tumor prostate ) : Castrate level testosterone ( &lt; 50 ng/dl ) 2 . Patient plan start abiraterone acetate enzalutamide concurrent sipuleucelT ( within six month initiation abiraterone acetate enzalutamide ) . 3 . Enrollment prior initiation abiraterone acetate enzalutamide sipuleucelT . B ) mCRPC visceral high risk disease preabiraterone/enzalutamide 1 . For patient adenocarcinoma prostate ( applicable patient small cell neuroendocrine tumor prostate ) : Castrate level testosterone ( &lt; 50 ng/dl ) 2 . Visceral OR high risk disease must meet one follow category : Visceral disease : Radiographic evidence liver , adrenal , pulmonary , brain metastasis High risk disease : Presence least 2 follow factor : Bone pain require opioids Anemia ( Hgb &lt; 13 g/dL ) Bone scan progression baseline &gt; 2 site metastatic disease Karnofsky Performance Status ( KPS ) 70 PSA double time &lt; 3 month 3 . Patient plan start abiraterone acetate enzalutamide . 4 . Enrollment prior initiation abiraterone acetate enzalutamide . C ) High volume metastatic castration sensitive prostate cancer ( mCSPC ) start hormonal therapy docetaxel chemotherapy decline docetaxel chemotherapy 1 . Testosterone &gt; 50 ng/dL 2 . High volume metastatic disease : visceral metastasis and/or 4 bone metastasis , least one outside axial ( spine pelvic bone ) skeleton 3 . Enrollment within 4 month initiation androgen deprivation therapy ( ADT ) . 4 . Patient plan start docetaxel addition ADT patient eligible docetaxel decline chemotherapy . 5 . Enrollment prior initiation docetaxel chemotherapy . D ) Enzalutamide abiraterone acetate resistant mCRPC 1 . For patient adenocarcinoma prostate ( applicable patient small cell neuroendocrine tumor prostate ) : Castrate level testosterone ( &lt; 50 ng/dl ) 2 . Evidence disease progression follow enzalutamide abiraterone acetate , define one following : Radiographic evidence disease progression define new bone scan lesion growth exist soft tissue/visceral/lymph node/bone metastasis determine investigator Clinical progression disease cutaneous lesion palpable lesion absence radiographic progression 1 . History intercurrent past medical psychiatric illness would make participation blood draw protocol difficult feasible discretion principal investigator coinvestigator ( ) . 2 . Treatment anthracycline ( include mitoxantrone ) within 1 week CTC collection , anthracyclines cause autofluorescence cell .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>